Linked Life Data

20158108

Source:http://linkedlifedata.com/resource/pubmed/id/20158108

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
2010-2-17
pubmed:abstractText
PPARgamma is a molecular target of thiazolidinedione class of antidiabetic drugs. Although activation of PPARgamma by thiazolidinedione improves insulin resistance in obese subjects, PPARgamma heterozygous knockout mice were resistant to a high-fat diet induced obesity and insulin resistance, suggesting that a moderate reduction of PPARgamma activity could be beneficial for the treatment of obesity and insulin resistance. This hypothesis was supported by genetic evidences consistently showing that the common Pro12Ala variant of PPARgamma2, which causes a moderate reduction in transcriptional activity and adipogenic potential, has been associated with reduced weight gain and improved insulin sensitivity. We here review PPARgamma antagonism as a potential remedy for obesity and diabetes.
pubmed:language
jpn
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Feb
pubmed:issn
0047-1852
pubmed:author
pubmed:issnType
Print
pubmed:volume
68
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
350-5
pubmed:dateRevised
2011-7-27
pubmed:meshHeading
pubmed:year
2010
pubmed:articleTitle
[PPARgamma antagonist as a potential drug for the treatment of obesity and diabetes].
pubmed:affiliation
Department of Metabolic Diseases, Graduate School of Medicine, the University of Tokyo.
pubmed:publicationType
Journal Article, English Abstract, Review